Novo Holdings has invested more than $22m of its $165m fund across four companies developing drugs meant to combat antimicrobial resistance.

Repair Impact Fund, a $165m vehicle owned by Denmark-based pharmaceutical firm Novo Holdings, has confirmed its first four investments. The vehicle provided $4.1m of funding for Minervax, a Netherlands-based company developing vaccines for pregnant women, as part of a €4.4m ($5m) round disclosed on Monday that included Sunstone Capital. The proceeds will support development of…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.